Florida [US], January 22 (ANI): A new study has found patients with cancer who receive chemotherapy -- and some targeted therapies may mount an inadequate immune response to COVID-19 vaccination.

The research has been published in the 'Mayo Clinic Proceedings: Innovation, Quality & Outcomes Journal'.

Also Read | SA vs IND Dream11 Team Prediction: Tips To Pick Best Fantasy Playing XI for South Africa vs India 3rd ODI 2022 in Cape Town.

"It is important for patients with cancer who are receiving chemotherapy to receive a COVID-19 vaccine," said Saranya Chumsri, M.D., a Mayo Clinic hematologist and oncologist, and author of the paper.

Dr Chumsri said this advice also applied to patients with cancer who are taking a CDK 4/6 inhibitors. These inhibitors are a newer class of medicines used to treat hormone-receptor-positive and HER2-negative breast cancers.

Also Read | Mumbai Fire: Blaze Erupts in 20-Storey Building, 7 Dead, Several Injured; Here's What We Know So Far.

Dr Chumsri said that while CDK 4/6 inhibitors are not conventionally considered to be as immunosuppressive as chemotherapy, her research on patients with breast cancer who take these drugs found that they exhibited less optimal neutralizing antibody activity.

Dr Chumsri recommended that antibody levels should be tested in these patients after vaccination, and they should consider receiving booster vaccinations for COVID-19.

Dr Chumsri anticipated having additional data later this year regarding broader immune responses to COVID-19 vaccinations, including cellular and antibody responses in patients receiving chemotherapy and targeted therapies with booster vaccinations. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)